MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5009/gnl250479

Медицинская библиотека · Gut and liver · 2026

Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea.

Shin Hyunjae, Hur Moon Haeng, Baek Yang Hyun, Lee Chun Kyon, Cho Yong Kyun, Lee June Sung, Jeong Jae Yoon, Jung Yong Jin, Kim Ja Kyung, Kim Moon Young, Seo Yeon Seok, Chung Woo Jin, Koh Moon Soo, Kim Jeong-Han, Lee Yun Bin, Cho Eun Ju, Lee Jeong-Hoon, Yu Su Jong, Yoon Jung-Hwan, Kim Yoon Jun

Клиническое исследование IV фазыEquivalence TrialСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND/AIMS: Tenofovir alafenamide (TAF) has emerged as a safe and effective alternative to entecavir (ETV) in the management of chronic hepatitis B (CHB). We aimed to evaluate the efficacy and safety of switching to TAF compared with maintaining ETV in patients with CHB who had achieved virologic suppression on ETV.

METHODS

In this multicenter, randomized, open-label, active-controlled, noninferiority clinical trial conducted at 13 Korean centers, 196 CHB patients who had experienced virologic suppression after ≥24 weeks of ETV therapy were randomized 1:1 to switch to TAF (n=95) or continue on ETV (n=101). The primary endpoint was the proportion of patients with hepatitis B virus (HBV) DNA <29 IU/mL at week 48 (per-protocol set). Secondary endpoints included alanine aminotransferase (ALT) normalization, hepatitis B surface antigen and hepatitis B e antigen serologic responses, and safety outcomes.

RESULTS

Among 188 patients in the per-protocol set (89 TAF, 99 ETV), the HBV suppression rate at week 48 was 100.0% in the TAF group and 99.0% in the ETV group (difference, 1.03%; one-sided 97.5% confidence interval, -0.96 to infinity). ALT normalization rates at week 48 were comparable between groups (55.0% in TAF vs 38.7% in ETV; p=0.26; American Association for the Study of Liver Diseases criteria). Hepatitis B e antigen seroconversion rates were also similar at week 48 (0.0% vs 12.5%; p=0.21). Safety profiles, including renal function, did not significantly differ between the two groups.

CONCLUSIONS

Switching from ETV to TAF was noninferior to continuing ETV in maintaining virologic suppression, with comparable biochemical, serologic, and safety outcomes. (ClinicalTrials. gov identifier NCT06000657).

Для цитирования: Shin Hyunjae, Hur Moon Haeng, Baek Yang Hyun, Lee Chun Kyon, Cho Yong Kyun, Lee June Sung, Jeong Jae Yoon, Jung Yong Jin, Kim Ja Kyung, Kim Moon Young, Seo Yeon Seok, Chung Woo Jin, Koh Moon Soo, Kim Jeong-Han, Lee Yun Bin, Cho Eun Ju, Lee Jeong-Hoon, Yu Su Jong, Yoon Jung-Hwan, Kim Yoon Jun. Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea.. Gut and liver. 2026. DOI: 10.5009/gnl250479.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.